News
-
-
-
PRESS RELEASE
STIF announces the sale by its main historical shareholder of 250 000 shares i.e., 4,9% of Company's share capital
STIF's main historical shareholder sells 4,9% of Company's shares in off-market block. The Burgos Family Group holds 51% of the share capital. Upcoming event: 2025 annual revenue publication on January 22, 2026 -
-
-
-
REGULATED PRESS RELEASE
KURMA PARTNERS, A MEMBER OF THE EURAZEO GROUP AND FOUNDING INVESTOR OF IMCHECK THERAPEUTICS, ANNOUNCES THE SALE OF THE BIOTECH COMPANY TO IPSEN FOR UP TO €1 BILLION
Kurma Partners, a member of the Eurazeo group, announces the sale of ImCheck Therapeutics to Ipsen for up to €1 billion. The biotech company focuses on immunotherapy for cancer treatment, confirming Kurma's success in creating and supporting biotech ventures -
-
PRESS RELEASE
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
Ipsen reports strong sales growth in first nine months of 2025, upgrades full-year guidance, and announces acquisition of ImCheck Therapeutics. Financial results and pipeline updates detailed -
